Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors
This study aimed to examine the role of very high-risk (VHR) factors (T3b–4 and Gleason score 9–10) for prognosis of clinically localized high-risk prostate cancer. We reviewed multi-institutional retrospective data of 1413 patients treated with radiotherapy (558 patients treated with external beam...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/14/3486 |
| _version_ | 1797527493905743872 |
|---|---|
| author | Hideya Yamazaki Gen Suzuki Koji Masui Norihiro Aibe Daisuke Shimizu Takuya Kimoto Kei Yamada Takumi Shiraishi Atsuko Fujihara Koji Okihara Ken Yoshida Satoaki Nakamura Haruumi Okabe |
| author_facet | Hideya Yamazaki Gen Suzuki Koji Masui Norihiro Aibe Daisuke Shimizu Takuya Kimoto Kei Yamada Takumi Shiraishi Atsuko Fujihara Koji Okihara Ken Yoshida Satoaki Nakamura Haruumi Okabe |
| author_sort | Hideya Yamazaki |
| collection | DOAJ |
| description | This study aimed to examine the role of very high-risk (VHR) factors (T3b–4 and Gleason score 9–10) for prognosis of clinically localized high-risk prostate cancer. We reviewed multi-institutional retrospective data of 1413 patients treated with radiotherapy (558 patients treated with external beam radiotherapy (EBRT) and 855 patients treated with brachytherapy (BT) ± EBRT. We introduced an index by simple summation of the number of VHR factors—VHR-0, VHR-1, and VHR-2. With median follow-up of 69.6 months, the 5-year biochemical disease free survival rate (bDFS), prostate cancer-specific mortality (PCSM), and distant metastasis-free survival (DMSF) rates were 59.4%, 7.65%, and 83.2% for the VHR-2 group, respectively; 86.7%, 1.50%, and 95.4% for the VHR-1 group, respectively; and 93.1%, 0.12%, and 98.2% for the VHR-0 group, respectively. The VHR-2 group had significantly worse bDFS, PCSM, and DMSF than the VHR-0 (hazard ratios: 4.55, 9.607, and 7.904, respectively) and VHR-1 (hazard ratios: 1.723, 2.391, and 1.491, respectively) groups. The VHR-2 group could be identified as a super high-risk group compared with other groups, and could be a good candidate for clinical trials using multimodal intensified treatments. Simple summation of the number of VHR factors is an easy and useful predictive index for bDFS, PCSM, and DMSF. |
| first_indexed | 2024-03-10T09:44:31Z |
| format | Article |
| id | doaj.art-eada6e3052644e0482ffc4f7cd3acc61 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T09:44:31Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-eada6e3052644e0482ffc4f7cd3acc612023-11-22T03:24:00ZengMDPI AGCancers2072-66942021-07-011314348610.3390/cancers13143486Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk FactorsHideya Yamazaki0Gen Suzuki1Koji Masui2Norihiro Aibe3Daisuke Shimizu4Takuya Kimoto5Kei Yamada6Takumi Shiraishi7Atsuko Fujihara8Koji Okihara9Ken Yoshida10Satoaki Nakamura11Haruumi Okabe12Department of Radiology, and Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, JapanDepartment of Radiology, and Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, JapanDepartment of Radiology, and Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, JapanDepartment of Radiology, and Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, JapanDepartment of Radiology, and Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, JapanDepartment of Radiology, and Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, JapanDepartment of Radiology, and Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, JapanDepartment of Radiology, and Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, JapanDepartment of Radiology, and Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, JapanDepartment of Radiology, and Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, JapanDepartment of Department of Radiology, Kansai Medical University, Hirakata 573-1010, JapanDepartment of Department of Radiology, Kansai Medical University, Hirakata 573-1010, JapanDepartment of Radiology, Ujitakeda Hospital, Uji-City 611-0021, JapanThis study aimed to examine the role of very high-risk (VHR) factors (T3b–4 and Gleason score 9–10) for prognosis of clinically localized high-risk prostate cancer. We reviewed multi-institutional retrospective data of 1413 patients treated with radiotherapy (558 patients treated with external beam radiotherapy (EBRT) and 855 patients treated with brachytherapy (BT) ± EBRT. We introduced an index by simple summation of the number of VHR factors—VHR-0, VHR-1, and VHR-2. With median follow-up of 69.6 months, the 5-year biochemical disease free survival rate (bDFS), prostate cancer-specific mortality (PCSM), and distant metastasis-free survival (DMSF) rates were 59.4%, 7.65%, and 83.2% for the VHR-2 group, respectively; 86.7%, 1.50%, and 95.4% for the VHR-1 group, respectively; and 93.1%, 0.12%, and 98.2% for the VHR-0 group, respectively. The VHR-2 group had significantly worse bDFS, PCSM, and DMSF than the VHR-0 (hazard ratios: 4.55, 9.607, and 7.904, respectively) and VHR-1 (hazard ratios: 1.723, 2.391, and 1.491, respectively) groups. The VHR-2 group could be identified as a super high-risk group compared with other groups, and could be a good candidate for clinical trials using multimodal intensified treatments. Simple summation of the number of VHR factors is an easy and useful predictive index for bDFS, PCSM, and DMSF.https://www.mdpi.com/2072-6694/13/14/3486very high-riskT3b–4Gleason 9–10prostate cancerbrachytherapy |
| spellingShingle | Hideya Yamazaki Gen Suzuki Koji Masui Norihiro Aibe Daisuke Shimizu Takuya Kimoto Kei Yamada Takumi Shiraishi Atsuko Fujihara Koji Okihara Ken Yoshida Satoaki Nakamura Haruumi Okabe Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors Cancers very high-risk T3b–4 Gleason 9–10 prostate cancer brachytherapy |
| title | Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors |
| title_full | Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors |
| title_fullStr | Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors |
| title_full_unstemmed | Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors |
| title_short | Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors |
| title_sort | novel prognostic index of high risk prostate cancer using simple summation of very high risk factors |
| topic | very high-risk T3b–4 Gleason 9–10 prostate cancer brachytherapy |
| url | https://www.mdpi.com/2072-6694/13/14/3486 |
| work_keys_str_mv | AT hideyayamazaki novelprognosticindexofhighriskprostatecancerusingsimplesummationofveryhighriskfactors AT gensuzuki novelprognosticindexofhighriskprostatecancerusingsimplesummationofveryhighriskfactors AT kojimasui novelprognosticindexofhighriskprostatecancerusingsimplesummationofveryhighriskfactors AT norihiroaibe novelprognosticindexofhighriskprostatecancerusingsimplesummationofveryhighriskfactors AT daisukeshimizu novelprognosticindexofhighriskprostatecancerusingsimplesummationofveryhighriskfactors AT takuyakimoto novelprognosticindexofhighriskprostatecancerusingsimplesummationofveryhighriskfactors AT keiyamada novelprognosticindexofhighriskprostatecancerusingsimplesummationofveryhighriskfactors AT takumishiraishi novelprognosticindexofhighriskprostatecancerusingsimplesummationofveryhighriskfactors AT atsukofujihara novelprognosticindexofhighriskprostatecancerusingsimplesummationofveryhighriskfactors AT kojiokihara novelprognosticindexofhighriskprostatecancerusingsimplesummationofveryhighriskfactors AT kenyoshida novelprognosticindexofhighriskprostatecancerusingsimplesummationofveryhighriskfactors AT satoakinakamura novelprognosticindexofhighriskprostatecancerusingsimplesummationofveryhighriskfactors AT haruumiokabe novelprognosticindexofhighriskprostatecancerusingsimplesummationofveryhighriskfactors |